Delivery Order SPE2DB20D7066-SPE2DB25FC4WC
- Not listed
- The Defense Logistics Agency awarded a $8,059.34 delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The award is non-competitive and structured as a firm fixed price delivery order, with an ultimate completion date of May 19, 2025. Performance of this contract will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,266.53 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $4,885.54. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is scheduled for completion by August 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Ondansetron ODT 8 mg tablets in a 30-count package. This is a firm fixed price delivery order with a ceiling value of $3,275.55 and an ultimate completion date of October 20, 2025. The contract was competitively awarded with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $26,647.13. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, is set for ultimate completion by December 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single task under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ondansetron ODT 8 mg tablets in a quantity of 30s. This is a firm fixed-price delivery order with a ceiling value of $4,655.43 and an ultimate completion date of August 22, 2025. The contract is not set-aside and was competitively awarded. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $13,399.76 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 15, 2025. Ondansetron is an antiemetic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count) with a ceiling value of $4,993.87. This is a firm fixed-price delivery order with an ultimate completion date of October 23, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of approximately $25.3K. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures, and scheduled for completion by September 12, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4WCDelivery Order
The Defense Logistics Agency awarded a $24.3K delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. Performance will be completed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. The ondansetron delivery supports the Defense Logistics Agency's medical supply chain operations, providing an antiemetic medication critical for managing nausea and vomiting across Department of Defense healthcare facilities and beneficiary populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.3k | 9/19/25 |